'Moxifloxacin' presentation slideshows

Approach to Selecting the Appropriate Antibiotic

Approach to Selecting the Appropriate Antibiotic. Teresa Lianne Beck, MD Assistant Professor Family Medicine Residency Program Adapted from Eddie Needham, MD with permission. Objectives.

1.42k views • 94 slides

A review of the safety of Moxifloxacin Hydrochloride

A review of the safety of Moxifloxacin Hydrochloride. Leonard Sacks MD Medical officer/DSPIDP. Moxifloxacin safety review. General safety Cardiac safety in vitro animal studies clinical studies phase 1+ 2 clinical studies phase 3. Patients valid for safety (worldwide).

556 views • 32 slides

PDPs and Alternative IP Management/Tech Transfer Strategies for Improved Global Health

PDPs and Alternative IP Management/Tech Transfer Strategies for Improved Global Health Gerald J. Siuta, Ph.D. Consultant, Business Development Biotechnology Industry Organization Annual Meeting Atlanta, GA May 20, 2009.

247 views • 24 slides

End TB Strategy

End TB Strategy. 1995. HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only. Full implementation of Global Plan: 2015 MDG target reached but TB not eliminated by 2050. Current rate of decline -2%/yr. China, Cambodia -4%/yr.

1.6k views • 24 slides

The TB Alliance-Bayer Moxifloxacin Deal

195 views • 19 slides

Moxifloxacin Impurity

Veeprho Pharmaceuticals s.r.o. is a manufacturer and supplier of Moxifloxacin Impurity D, Moxifloxacin Impurity A, Moxifloxacin Impurity C, 8-Hydroxy Moxifloxacin, Methoxy Quinoline Ester Impurity and Moxifoxacin Decarboxylated Compound. See more at : - http://www.veeprhopharma.com/Moxifloxacin-Impurity-Manufacturer-Supplier.php

445 views • 12 slides

Antibiotic Resistance among invasive pneumococcal Isolates from Southwest Sweden 1998-2001

Antibiotic agent. MIC 50. MIC 90. 1. Other. 1. median. 90 percentile. Other. 12,5%. 14,3%. mg/L. mg/L. 17,8%. 12F. Penicillin G. 0.016. 0.023. 9V. 9V. 8,6%. Erythromycin . 0.190. 0.250. 14. 15,6%. 8,5%. Clindamycin . 0.190. 0.250. 43,8%. 9N. 14. 19A. Tetracycline .

146 views • 1 slides

P 694

P 694. Safety and efficacy of PTK 0796 (Omadacycline) as treatment of complicated skin and soft tissue infection ( cSSTI ) Gary J. Noel*, Michael Draper, Howard Hait, S. Ken Tanaka ( Boston, Massachusetts US). 75 Kneeland Street Boston , MA 02111 617.275.0040 gnoel@pa ratekpharm.com.

189 views • 1 slides